@Article{信息:doi 10.2196 / / jmir。4541，作者=“王科健万梅王瑞生翁祖全”，标题=“网络药物重新定位的机会:寻找潜在的降压药物伴低血压不良事件”，期刊=“J医学互联网研究”，年=“2016”，月=“4”，日=“01”，卷=“18”，数=“4”，页数=“e76”，关键词=“网络药物重新定位;FDA不良事件报告系统;FAERS;openFDA;大数据;抗高血压药物;背景:药物重新定位是指现有药物开发新适应症的过程。作为人类药物反应的表型指标，临床副作用可能为药物重新定位提供直接的信号和独特的机会。目的:我们的目的是找出与低血压不良反应(即高血压的相反情况)频繁相关的药物，这些药物可能成为潜在的抗高血压药物。 Methods: We systematically searched the electronic records of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) through the openFDA platform to assess the association between hypotension incidence and antihypertensive therapeutic effect regarding a list of 683 drugs. Results: Statistical analysis of FAERS data demonstrated that those drugs frequently co-occurring with hypotension events were more likely to have antihypertensive activity. Ranked by the statistical significance of frequent hypotension reporting, the well-known antihypertensive drugs were effectively distinguished from others (with an area under the receiver operating characteristic curve > 0.80 and a normalized discounted cumulative gain of 0.77). In addition, we found a series of antihypertensive agents (particularly drugs originally developed for treating nervous system diseases) among the drugs with top significant reporting, suggesting the good potential of Web-based and data-driven drug repositioning. Conclusions: We found several candidate agents among the hypotension-related drugs on our list that may be redirected for lowering blood pressure. More important, we showed that a pharmacovigilance system could alternatively be used to identify antihypertensive agents and sustainably create opportunities for drug repositioning. ", issn="1438-8871", doi="10.2196/jmir.4541", url="//www.mybigtv.com/2016/4/e76/", url="https://doi.org/10.2196/jmir.4541", url="http://www.ncbi.nlm.nih.gov/pubmed/27036325" }